Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status (DHA-RICHOIL)
Primary Purpose
Hypercholesterolemia
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Docosahexaenoic acid
Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)
Germ oil
National Cholesterol Education Program (NCEP) Step I Diet
Sponsored by
About this trial
This is an interventional treatment trial for Hypercholesterolemia focused on measuring Hypercholesterolemic children, Docosahexaenoic acid, Eicosapentaenoic acid, Blood lipid profile
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of primary hypercholesterolemia (total cholesterol levels > 200 mg/dl before entering the study)
- BMI >3°and < 97° percentile for age
- First referring to our Lipid Clinic
Exclusion Criteria:
- Secondary dyslipidemia
- Obesity
- Step I diet or any dietary supplement before entering the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Placebo
DHA+EPA group
DHA Group
Arm Description
12 hypercholesterolemic children 3-13 years of age
12 hypercholesterolemic children 3-13 years of age
12 hypercholesterolemic children 3-13 years of age
Outcomes
Primary Outcome Measures
Plasma Docosahexaenoic Acid (DHA) levels in DHA group and DHA+EPA group versus placebo after intervention
Secondary Outcome Measures
Blood lipid profile variation in DHA Group and DHA+EPA Group versus placebo group after intervention
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00678067
Brief Title
Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status
Acronym
DHA-RICHOIL
Official Title
Effects of Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid(EPA)Supplementation on DHA Plasmatic Status and Blood Lipid Profile in Hypercholesterolemic Children in Addition to National Cholesterol Education Program Step I Diet
Study Type
Interventional
2. Study Status
Record Verification Date
May 2008
Overall Recruitment Status
Completed
Study Start Date
June 2005 (undefined)
Primary Completion Date
November 2006 (Actual)
Study Completion Date
November 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Milan
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To examine whether Docosahexaenoic Acid (DHA) and Docosahexaenoic + Eicosapentaenoic Acids (DHA+EPA) supplementation in addition to National Cholesterol Education Program Step I Diet in Hypercholesterolemic Children increases Docosahexaenoic Acid (DHA) plasma levels in the 2 intervention groups versus placebo. Secondary outcome measure: effect of DHA and DHA+EPA supplementation on blood lipid profile
Detailed Description
In a double-blind placebo-controlled trial 36 hypercholesterolemic children, 3-13 years of age, 19 males and 17 females were put on National Cholesterol Education Program (NCEP)Step-I diet and randomised into 3 groups to receive 500 mg/day of purified Docosahexaenoic Acid (DHA), Docosahexaenoic Acid plus Eicosapentaenoic Acid (DHA+EPA) mixture (228 + 208 mg/day respectively), or wheat germ oil as placebo. They underwent at baseline and after a 4 month treatment: EPA and DHA levels in total plasma and in phospholipids, triglycerides, cholesteryl esters; dietary habits by food frequency questionnaire; blood lipid profile (total cholesterol, HDL cholesterol, triglycerides levels)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia
Keywords
Hypercholesterolemic children, Docosahexaenoic acid, Eicosapentaenoic acid, Blood lipid profile
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
12 hypercholesterolemic children 3-13 years of age
Arm Title
DHA+EPA group
Arm Type
Experimental
Arm Description
12 hypercholesterolemic children 3-13 years of age
Arm Title
DHA Group
Arm Type
Experimental
Arm Description
12 hypercholesterolemic children 3-13 years of age
Intervention Type
Dietary Supplement
Intervention Name(s)
Docosahexaenoic acid
Other Intervention Name(s)
DHA
Intervention Description
Soft capsules 500 mg/each; 1 capsule/day for 4 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)
Other Intervention Name(s)
DHA and EPA mixture
Intervention Description
Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
Intervention Type
Dietary Supplement
Intervention Name(s)
Germ oil
Other Intervention Name(s)
wheat germ oil
Intervention Description
Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
Intervention Type
Other
Intervention Name(s)
National Cholesterol Education Program (NCEP) Step I Diet
Other Intervention Name(s)
Dietary intervention, Dietary recommendations
Intervention Description
Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
Primary Outcome Measure Information:
Title
Plasma Docosahexaenoic Acid (DHA) levels in DHA group and DHA+EPA group versus placebo after intervention
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Blood lipid profile variation in DHA Group and DHA+EPA Group versus placebo group after intervention
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of primary hypercholesterolemia (total cholesterol levels > 200 mg/dl before entering the study)
BMI >3°and < 97° percentile for age
First referring to our Lipid Clinic
Exclusion Criteria:
Secondary dyslipidemia
Obesity
Step I diet or any dietary supplement before entering the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Silvia Decarlis, MD
Organizational Affiliation
Dept. of Pediatrics, San paolo Hospital, University of Milan, Italy
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
24228803
Citation
Verduci E, Agostoni C, Radaelli G, Banderali G, Riva E, Giovannini M. Blood lipids profile in hyperlipidemic children undergoing different dietary long chain polyunsaturated supplementations: a preliminary clinical trial. Int J Food Sci Nutr. 2014 May;65(3):375-9. doi: 10.3109/09637486.2013.858239. Epub 2013 Nov 14.
Results Reference
derived
Learn more about this trial
Effects of Docosahexaenoic and Eicosapentaenoic Acids in Hypercholesterolemic Children Plus Diet on Docosahexaenoic Acid (DHA) Status
We'll reach out to this number within 24 hrs